A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 5-day Continuous Intravenous Dosing Of ON 01910.Na Administered Every 2 Weeks in Patients With Intermediate-1, Intermediate-2, or High Risk Myelodysplastic Syndrome (MDS)
This is a single center, open label, phase 1/2 study in which two to thirty three patients
with Intermediate-1, Intermediate-2, or High risk MDS will receive ON 01910.Na as a
intravenous continuous infusion (IVCI) over 24 hours for 5 consecutive days every 2 weeks.
In the phase 1 component of this trial the maximum tolerated dose of ON1910.Na in patients
with Intermediate-1, Intermediate-2 or High Risk myelodysplastic syndromes will be
determined. A standard "3+3" dose escalation scheme will be followed with up to six
patients treated at the 800 mg/m2/day dose level. Patients will be observed for 2 cycles
before dose escalation occurs. If none of the initial three patients in the 800 mg/m2/day
cohort experience dose-limiting toxicity (DLT), during the first two cycles, then a new
cohort of three patients will be treated at the 1500 mg/m2/day dose level. If none of the
initial three patients in the 1500 mg/m2/day cohort experience DLT during the first two
cycles, three additional patients will be treated at the 1500 mg/m2/day level. If no more
than one of the six patients at the 1500 mg/m2/day dose level experiences a DLT, then that
dose level will be confirmed as the MTD and no further dose escalation will occur.
If one of the three patients in the 800 mg/m2/day cohort experiences DLT during the first
two cycles, then up to three additional patients will be treated at the same dose level.
Escalation to 1500 mg/m2/day will proceed if only one of the six patients experiences DLT at
the 800 mg/m2/day dose level. If two or more patients in the 800 mg/m2/day cohort experience
DLT during the first two cycles, then the maximum tolerated dose (MTD) will have been
exceeded, no further dose escalation will occur, and a full safety review will determine if
further enrollment of patients will proceed.
If the 800 mg/m2/day dose level is under consideration as the MTD (i.e. if ≥ 2 patients
experience DLT at the 1500 mg/m2/day dose level), and only three patients were treated
before escalation to 1500 mg/m2/day, then three additional patients will be accrued. If no
more than one of the six patients at the 800 mg/m2/day dose level experiences a DLT, then
that dose level will be confirmed as the MTD.
Once the phase 1 portion of the study is completed, accrual to the phase 2 portion will
begin. Patients treated at the MTD during the phase 1 portion will be included in the phase
2 component and will be evaluated for response and secondary end points.
The total study duration is 29 weeks, which includes a 2-week screening phase, a 23-week
dosing phase, and a 4-week follow-up phase that begins after the last dose of ON 01910.Na.
Patients will be assessed for response and will undergo follow up.
Patients who drop out for any reason will not be replaced. Patients who achieve a complete
or partial response or stabilization of their disease by week 25 are eligible to receive an
additional 24 weeks of ON 01910.Na at the same dose they received during the first 24 weeks
of treatment(800 or 1500 mg/m2/day IVCI for 5 days Q2W).
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose (in Phase 1)
1 month
Yes
Virginia Klimek, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
Onconova 04-11
NCT00867061
March 2009
September 2010
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |